CellXpress.ai Automated Cell Culture System

The CellXpress.ai® Automated Cell Culture System from Molecular Devices streamlines scalable, reproducible brain organoid generation from human iPSCs. By combining automated liquid handling, incubation, imaging, and AI-driven analysis, it reduces variability and contamination risk while enabling consistent long-term culture and monitoring.

In this application note, discover how automated feeding improves reproducibility, how functionally active organoids match manual methods, and how integrated imaging supports continuous developmental monitoring, advancing scalable, reliable neuro research.

Discover how the CellXpress.ai® Automated Cell Culture System transforms iPSC maintenance and expansion into a fully automated, walk-away workflow. This application note showcases a machine learning–enabled solution that monitors colony confluency and differentiation in real time, triggering automated passaging or excluding wells based on user-defined thresholds. By integrating liquid handling, imaging, and intelligent decision-making, the system reduces manual workload, improves consistency, and preserves stem cell quality.

Ideal for scaling up stem cell research, this approach ensures reproducibility, saves time and reagents, and empowers scientists to focus on discovery, not routine cell culture.

Discover how the CellXpress.ai® Automated Cell Culture System and the ImageXpress® HCS.ai High-Content Screening System deliver a fully automated, AI-powered workflow for compound toxicity screening using healthy human intestinal organoids.

This application note highlights a scalable solution that integrates automated organoid culture, compound dosing, and high-content imaging with machine learning–driven phenotypic analysis. By combining deep learning segmentation (SINAP) and phenotypic classification (Phenoglyphs™) found in IN Carta® Image Analysis Software, the system accurately distinguishes between cytotoxic, cytostatic, and viable organoid responses.

Discover how to overcome the challenges of scaling 3D organoid models for high-throughput drug discovery. This comprehensive guide delivered in partnership with Molecular Devices explores innovative solutions for automating organoid culture, screening, and analysis.

Download this SelectScience guide to explore:

• Patient-derived 3D Ready™ Organoids and Expansion Services
• The CellXpress.ai® Automated Cell Culture System
• High-content imaging with ImageXpress® HCS.ai and IN Carta® software
• AI-powered workflows for toxicity screening and phenotypic profiling

Ideal for researchers seeking reproducible, scalable, and human-relevant models to accelerate drug development and personalized medicine.

Resource details:

• Document type: SelectScience guide
• Page count: 36
• Read time: 54 mins
• Edition: 1st

Explore an automated, dome-free workflow for T-cell screening using patient-derived colorectal cancer organoids and the CellXpress.ai® Automated Cell Culture System. This poster showcases how the system streamlines organoid seeding, T-cell co-culture, and high-content imaging—enabling precise, high-throughput analysis of T-cell penetration behavior in a 3D tumor-like environment. The workflow leverages IN Carta® Image Analysis Software to quantify chemotactic responses to varying PMA concentrations, offering a powerful model for evaluating immunotherapeutic efficacy.

This application note demonstrates the automation of a compound testing assay for toxicity assessment using human and mouse 3D intestinal organoids. Intestinal organoids were cultured, passaged, and expanded in Matrigel domes in 24 wells using the CellXpress.ai™ Automated Cell Culture System. The ImageXpress® HSC.ai High Content Screening System was used for the evaluation of toxicity effects by imaging and analysis of phenotypic changes in 3D organoids.

Explore how automation transforms manual, error-prone workflows into scalable, reproducible systems. This guide covers the cell culture journey from seeding to passaging, provides real-world automation examples, and highlights the role of AI-driven systems like CellXpress.ai™ in advancing drug discovery and 3D biology research.

In this application note, we demonstrate how the CellXpress.ai™ Automated Cell Culture System uses AI-driven image analysis to enable fully automated passaging, media exchange, and expansion of HCT116 and CHO cells, improving reproducibility, efficiency, and walk-away cell maintenance for drug discovery and research.

This application note details how the CellXpress.ai® Automated Cell Culture System integrates AI-powered imaging and machine learning to automate 3D organoid culture. It covers methods, workflows, and results for mouse intestinal, human intestinal, and colorectal cancer organoids, demonstrating improved reproducibility, reduced variability, and a scalable approach for organoid-based research.

Producing patient-derived organoids (PDOs) at scale has become a major bottleneck in adopting these models for high-throughput and repeat-use applications such as pooled CRISPR screening, hit-to-lead screening, and compound screening. Traditional culture methods are slow, labor-intensive, and often yield inconsistent organoid models, making it difficult to meet the demands of these applications.

In this eBook, we explore these challenges in depth and share proven strategies to help you scale up your organoid research. Learn how to obtain consistent, high-quality PDOs and integrate them seamlessly into high-throughput assays.

Friday, October 3, 2025 at 16:00 BST | 17:00 CEST | 11:00 EDT | 8:00 PDT

While cell-based models and assays are basic tools for drug development and biological research, tissue culture remains the most routine, hands-on, and time-consuming part of biological studies. Because of protocol complexity, sensitivity to errors, and substantial training requirements, these processes are difficult to automate and to ensure reproducibility and quality, especially when working with complex cell models such as organoids.

In this webinar, Dr. Oksana Sirenko from Molecular Devices, will present an overview of how AI-powered decision-making and automation create a fully automated cell culture platform. Discover how automation can not only alleviate these time-sensitive and highly routine tasks from the scientist, but can also reduce human error and inconsistencies associated with manual processes.

Key learning objectives:

• Explore how automated cell culture can lead to more reproducible assay outcomes
• Discover how automated, AI-powered decision making enables the creation of fully walkaway workflows
• Learn how complex cell models such as organoids, including brain organoids, and iPSCs can be cultured

Who should attend?

• Core facility leaders or managers.
• Researchers interested in scaling up their 3D biology workflows.
• Researchers working in high-throughput screening, high-content screening, or toxicology workflows.

Certificate of attendance
If you attend the live webinar, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand webinar, you can request a certificate of attendance by emailing editor@selectscience.net.

Friday, February 27 at 15:00 GMT | 16:00 CET | 10:00 EST | 07:00 PST

Manual cell culture workflows can be time-consuming, inconsistent, and difficult to expand, particularly when working with advanced models such as iPSCs and brain organoids. But automation is changing that.

Join this 20-minute SelectScience TechTalk, held in partnership with Molecular Devices, to explore how AI-driven automation is reshaping cell culture across pharmaceutical R&D and core facilities. Learn how labs are reducing hands-on time, minimizing variability, and creating more consistent, traceable processes from start to finish.

During the session, we’ll highlight the capabilities of the CellXpress.ai® Automated Cell Culture System, a fully integrated platform designed to automate complex cell culture workflows while enabling continuous monitoring and complete cell journey traceability.

Whether you’re leading drug discovery programs or overseeing shared lab operations, you’ll gain practical insights to help you:

• Increase throughput without increasing headcount
• Improve data consistency across experiments and sites
• Standardize protocols to reduce variability
• Scale operations with confidence

Key learning objectives:

• Learn how even complex cell culture workflows can be reliably automated, reducing operator variability and increasing lab efficiency
• See how AI-powered decision-making enables the entire cell culture process to be automated while reducing human error
• How to incorporate automated cell culture into a wider automated workflow
• How to continuously monitor cell culture over time while being able to trace the entire cell journey

Who should attend?

• Lab managers
• Principal investigator
• Director of lab operations

Certificate of attendance
If you attend the live TechTalk, you will automatically receive a certificate of attendance, including a learning outcomes summary, for continuing education purposes.

If you view the on-demand TechTalk, you can request a certificate of attendance by emailing editor@selectscience.net.

TechTalk details

• Cost: Free to attend
• Location: Online
• Duration: 20 minutes

Registration is required to secure your place. If you register but can’t attend live, you will receive a link to the on‑demand recording once it becomes available

One of the biggest challenges in modern drug discovery is that 90% of candidates fail during development, largely due to safety concerns around liver toxicity. This high failure rate can often be linked to the limitations of traditional 2D cell cultures used in early testing. As a result, there is a critical need to develop more predictive in vitro assays, especially for assessing hepatotoxicity. In this presentation, Dr. Oksana Sirenko, Senior Manager of Assay Development at Molecular Devices, explores how high-content imaging, along with AI and machine learning, can serve as powerful tools to investigate drug effects and predict potential toxicity more accurately.

This video was filmed at SLAS Europe 2025.

Cardiovascular disease is the leading cause of death worldwide, claiming 34 lives every minute. Cardiotoxicity is also a significant reason for drug withdrawals during development. To tackle these challenges, Molecular Devices and HeartBeat.Bio have teamed up to provide automated solutions that better mimic human cardiac physiology.

In this presentation, Dr. Florian Fuchs, CTO of HeartBeat.Bio, and Dr. Oksana Sirenko, Senior Manager of Assay Development at Molecular Devices, showcase how automated organoid culture and high-throughput screening are facilitating the effective use of cardioids in drug discovery and preclinical cardiotoxicity testing. Learn how cardioids, automation, and high-throughput workflows are revolutionizing the future of cardiac drug development.

This video was filmed at SLAS Europe 2025.

Dr. Florian Fuchs, CTO of HeartBeat.Bio, and Dr. Oksana Sirenko of Molecular Devices present: Transforming cardiovascular research with the CellXpress.ai Automated Cell Culture System: Unleashing the potential of 3D biology in automated high-throughput cardioids for drug discovery and toxicity screening.

This presentation was filmed at SLAS Europe 2024.

Dr. Oksana Sirenko, Senior Manager of Assay Development at Molecular Devices, presents: Transforming cardiovascular research with CellXpress.ai: Unleashing the potential of 3D biology in automated high-throughput cardioids for drug discovery and toxicity screening.

This presentation was filmed at SLAS Europe 2024.